ibrutinib + thalidomide

Ibrutinib + thalidomide is an investigational combination of two small molecule drugs. Ibrutinib is a Bruton’s tyrosine kinase inhibitor that blocks B-cell receptor signaling, leading to inhibition of malignant B-cell proliferation and survival. It is primarily used in the treatment of various B-cell malignancies such as chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia[2][7]. Thalidomide is an immunomodulatory agent with anti-inflammatory and antiangiogenic properties; it inhibits tumor necrosis factor-alpha production and modulates immune response. Thalidomide has been used in multiple myeloma and certain other hematologic malignancies. The combination aims to leverage complementary mechanisms—targeted inhibition of BTK by ibrutinib with the immunomodulatory effects of thalidomide—to enhance antitumor activity in hematological cancers.

Other names

PCI-32765PCI32765PCI 32765CC-5013CC5013CC 5013